洞察市场格局
解锁药品研发情报

客服电话

400-9696-311
医药数据查询

【ChiCTR1900028604】Clinical Observation of Combined Acupuncture Points with Deep Puncture at the Acupoint Jingming BL1 for Glaucoma Treatment

基本信息
登记号

ChiCTR1900028604

试验状态

尚未开始

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2019-12-28

临床申请受理号

/

靶点

/

适应症

青光眼

试验通俗题目

Clinical Observation of Combined Acupuncture Points with Deep Puncture at the Acupoint Jingming BL1 for Glaucoma Treatment

试验专业题目

Clinical Observation of Combined Acupuncture Points with Deep Puncture at the Acupoint Jingming BL1 for Glaucoma Treatment

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

47100

联系人通讯地址
请登录查看
临床试验信息
试验目的

1. To assess the effectiveness of deep puncture treatment in lowering the IOP in POAG patients. 2. To assess the effectiveness of deep puncture treatment in improving visual acuity in POAG patients. 3. To assess the safety of deep puncture at acupoint Jingming BL1 reaching a depth of 40mm from an angle of 85 degree.

试验分类
请登录查看
试验类型

单臂

试验分期

回顾性研究

随机化

Selection of participants is done according to inclusion and exclusion criteria by principal investigator.

盲法

No

试验项目经费来源

Self-funded

试验范围

/

目标入组人数

25

实际入组人数

/

第一例入组时间

2020-02-03

试验终止时间

2020-06-30

是否属于一致性

/

入选标准

Study participants will be those who are: 1. of either gender; 2. > 18 and < 80 years of age; 3. diagnosed as POAG according to the diagnostic criteria of POAG used in current ophthalmology practice; 4. not legally blind by the official definition of having central visual acuity of 20/200 or less in the better eye with corrective lenses, and /or a visual field of 20 degrees or less in the better eye; 5. never before treated with deep acupuncture at acupoint Jingming BL1 for glaucoma.;

排除标准

Exclusion criteria will be as follows: 1. Participants with cardiovascular, kidney, liver, or hematopoietic system diseases, mental health disorders, cancer or other severe diseases for whom acupuncture may be inappropriate or unsafe; 2. Participants with other diseases that could interfere with acupuncture treatment, e.g., clotting disorders or leukopenia, active skin infection, epilepsy, or on anticoagulant therapy (aspirin, warfarin etc); 3. Participants with a pacemaker, metal allergy, or severe fear of needles; 4. Women who are pregnant or lactating; 5. Participants who have difficulties in attending the trial (e.g. paralysis, cancer, dementia, drug addiction, time constraints, surgical operation).;

研究者信息
研究负责人姓名
请登录查看
试验机构

马来西亚雅兰大学

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

43000

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

最新临床资讯